Insights · Regulated Communications

What Is a Communications Transfer Package? Closing Biopharma's R&D-to-Commercial Communications Gap

Edited by Abhi BasuPublished November 9, 2026Updated November 9, 2026

Key takeaways

A Communications Transfer Package (CTP) is a defined, source-linked set of disease, mechanism and program language handed from R&D-side to launch-side communications at the Phase 2-to-Phase 3 transition.
The Handoff Gap is structural: roughly 7 in 10 Phase 2 drugs never reach Phase 3, and Phase 3 alone can run one to four years, so no team owns the words in between.
Even without a Phase 2 press release, the precedent exists in filings, congress posters, registries and investor decks. It is scattered, not missing.
FDA scrutiny of drug promotion rose sharply in 2025, and AI answer engines read old and new disclosures side by side, so consistency across a program's record matters more than ever.
The model is borrowed from manufacturing technology transfer: a sending unit, a receiving unit, a defined package and a gate before Phase 3 topline.

A Communications Transfer Package (CTP) is a defined, source-linked set of disease, mechanism and program language that the R&D-side communications team hands to the launch-side team at the Phase 2-to-Phase 3 transition, modeled on manufacturing's technology transfer package. The term was introduced by Signal Fidelity Group in 2026.

Biopharma would never move a molecule from Phase 2 to Phase 3 manufacturing on a handshake. Yet it moves the words about that molecule exactly that way, so launch teams re-source and re-clear a disease story the company already substantiated years earlier. Manufacturing has a tech transfer package. Communications has an inbox.

What is the Handoff Gap in biopharma communications?

The Handoff Gap is the period between a drug's Phase 2 readout and its Phase 3 topline when no team formally owns the sourced language about the disease and the program. R&D communications supports early readouts, then moves to the next asset. Product or brand communications arrives later, often with a new agency, and rebuilds the disease story from scratch.

Why does the handoff break?

Three reasons, all structural:

Attrition. Roughly 7 in 10 drugs in Phase 2 never reach Phase 3. FDA puts the share that moves on at about 33%, and Citeline's 2014–2023 data at 28%. So early communications is built for the moment, not for a future brand.
Time. FDA describes Phase 3 trials as running one to four years. Over that span, people change roles and agencies change.
Scatter. Cleared language lives in press releases, SEC filings, congress posters, trial registries and investor decks, owned by different functions.

What if there was no Phase 2 press release?

The precedent usually still exists. Public companies describe pipeline programs and target diseases in their annual reports, medical teams present early data at congresses, and trial registries carry study designs. A CTP gathers that already-reviewed language, with sources, so the launch team does not re-research it.

Why does this matter more now?

Two changes. First, FDA scrutiny of drug promotion rose sharply. On September 9, 2025, FDA announced about 100 cease-and-desist letters in one sweep and said it is "already implementing AI and other tech-enabled tools to proactively surveil and review drug ads." Its posted untitled letters went from 5 in 2024 to 62 in 2025. That raises the bar for showing where every launch claim came from.

Second, AI answer engines read a company's old and new disclosures together. When a program's Phase 2 and Phase 3 materials cite different disease figures, those engines can blend or mix them in the answers patients, physicians and investors see. This second point is Signal Fidelity Group's working hypothesis, which we are testing with answer audits.

What goes in a Communications Transfer Package?

Disease facts: prevalence, incidence, burden and current standard of care, each with its source and date. Supplied by R&D communications with medical.
Mechanism language: the cleared description of how the drug works. Supplied by R&D communications with medical and regulatory.
Program record: study names, designs, registry numbers and endpoints as previously described. Supplied by clinical and R&D communications.
Precedent log: every public disclosure of the program, including releases, filings, posters and decks. Supplied by R&D communications and investor relations.
Change log: what was updated between readouts and why. Kept by the package owner.
Open questions: facts that are stale, disputed or not yet sourced. Kept by the package owner.

How is a CTP different from a scientific communication platform or a claims library?

A scientific communication platform guides medical affairs' scientific exchange. A claims library governs promotional claims after approval. A CTP covers corporate and product communications language before approval, and its job is continuity from one team to the next.

Who owns the CTP?

The sending unit (R&D or pipeline communications) builds and maintains it. The receiving unit (product or brand communications and its agency) accepts it at an agreed gate before Phase 3 topline. This mirrors the sending-unit and receiving-unit model in WHO's guideline on technology transfer in pharmaceutical manufacturing.

The CTP checklist

Use this at your next Phase 2 readout.

Stage 1. Capture (sending unit, at the Phase 2 readout)

Name one owner for the package.
Pull every disease fact used to date, each with source, date and where it was used.
Record the cleared mechanism description, word for word.
Record the program as described publicly: study names, designs, registry numbers, endpoints.
Log every public disclosure: releases, annual and quarterly filings, congress posters and abstracts, investor decks, registry entries.
Note what was deliberately not said, and why.

Stage 2. Maintain (the quiet years between readouts)

Review disease figures when new epidemiology publishes, and log each change and its reason.
Add every new disclosure to the precedent log.
Flag stale or disputed facts as open questions instead of deleting them.
Check what AI answer engines say about the program and the disease, and log any figure that conflicts with the package.

Stage 3. Hand over (receiving unit, at an agreed gate before Phase 3 topline)

Set the gate date early enough that the launch team builds from the package, not beside it.
Walk the receiving team and agency through the package, including open questions.
The receiving team confirms each fact or sends it back for sourcing.
Draft the "About the disease" and "About the study" sections from the package, with sources attached for review.
Agree the rule: a fact not in the package is sourced and added before it is used.

Key terms

Communications Transfer Package (CTP): a defined, source-linked set of disease, mechanism and program language handed from R&D-side to launch-side communications at the Phase 2-to-Phase 3 transition.
The Handoff Gap: the period between a drug's Phase 2 readout and its Phase 3 topline when no team formally owns the sourced language about the disease and the program.
Sending unit / receiving unit: the team that hands over the package and the team that accepts it, borrowed from pharmaceutical technology transfer.

How Signal Fidelity Group supports CTPs

CAMS keeps each approved message with its source and review record, which makes it a natural home for a CTP. CommsRx carries that record through the launch sequence from Phase 3 readout onward.

Sources

Frequently asked

What does CTP stand for in pharma communications?

Communications Transfer Package: the sourced disease and program language handed from R&D communications to the launch team at the Phase 2-to-Phase 3 transition.

What is the Handoff Gap?

The Handoff Gap is the period between a drug's Phase 2 readout and its Phase 3 topline when no team formally owns the sourced language about the disease and the program.

When should a CTP be handed over?

At an agreed gate before Phase 3 topline, early enough that the launch team and its agency build from it rather than in parallel with it.

Is a CTP a regulatory requirement?

No. It is a working discipline borrowed from manufacturing technology transfer, where a sending unit hands a documented package to a receiving unit.

How is a CTP different from a claims library?

A claims library governs promotional claims after approval. A CTP covers corporate and product communications language before approval, and its job is continuity from the R&D-side team to the launch team.